CENTENIAL SURGICAL SUTURE LTD.

Centenial Surgical Suture Ltd has announced the retirement of Mr. Sanjay Sohani, President - Production and a Senior Management Personnel (SMP). His retirement is effective from the close of business hours on June 20, 2026. Consequently, he will also cease to be an SMP from the same date. The company has provided this intimation as per Regulation 30 of the SEBI (LODR) Regulations, 2015. Further details are enclosed as Annexure I.

Centennial Surgical Suture Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct. The trading window will be shut from Wednesday, July 1, 2026, until 48 hours after the dissemination of the financial results for the quarter ended June 30, 2026. This measure is applicable to all designated persons within the company.

Centenial Surgical Suture Ltd's board meeting on May 30, 2026, approved the standalone audited financial results for the quarter and year ended March 31, 2026. The statutory auditors issued an unmodified opinion for the financial year ended March 31, 2026. The meeting also included a disclosure of related party transactions.

Centenial Surgical Suture Ltd has released its standalone audited financial results for the quarter and year ended March 31, 2026. The results were reviewed by the Audit Committee and approved by the Board of Directors on May 30, 2026. The company's operations consist of one segment: Medical Devices. The standalone audited financial results are available on the BSE Limited and company websites.

Centenial Surgical Suture Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the standalone audited financial results for the quarter and year ended March 31, 2026, as per Regulation 33 of the SEBI (LODR) Regulations, 2015. The approved results will be uploaded on the BSE Limited website after the meeting.

Centenial Surgical Suture Ltd has requested BSE to investigate potential misuse and unethical trading practices related to significant price fluctuations in its equity shares (Scrip no. 531380). The company observed abnormal price increases and declines unsupported by corporate announcements or material business changes, suggesting possible manipulative trades. They provided details of trading activity up to May 8, 2026, highlighting a substantial increase in share price and thin trading volumes. The company suspects price rigging and urges BSE to examine the legality and genuineness of transactions, especially those involving repeated buyers and unnatural trading patterns.

Centenial Surgical Suture Ltd has announced that the trading window for dealing in the company’s securities will be closed from Wednesday, April 1, 2026 until 48 hours after the financial results of the company for the quarter and year ended March 31, 2026 have been disseminated to the stock exchange. This announcement is in accordance with the Company’s Code of Conduct for prevention of Insider Trading under the SEBI (Prohibition of Insider Trading) Regulations, 2015, and BSE circular LIST / COMP / 01 / 2019-20 dated 02nd April, 2019.

Centenial Surgical Suture Ltd, Scrip no.: 531308, has reported unusual trades in the company shares on BSE Limited. The company has observed individuals selling and purchasing 1, 2, 3, 4, 5 equity shares during the period from February 06, 2026 to February 13, 2026. The trading details and contact information of these individuals are provided in annexure A. The company suspects manipulative, unethical, and unusual trades in their scrip and requests urgent attention from the authorities. The increase in the scrip price during the past few months does not align with the actual financial performance of the company, suggesting manipulations committed by group entities. The company believes that the anti-money laundering agency's investigation will reveal that several entities and individuals have derived huge profits while causing loss to genuine investors. The illegal profits were routed through various accounts of different entities and individuals, with some instances of the father selling to the son and the son selling to the father. The company hopes that these illegal activities can be further probed and requests an investigation under various sections of the Securities and Exchange Board of India Act (SEBI Act), 1992.

The Board of Directors of Centenial Surgical Suture Ltd. approved the standalone un-audited financial results for the quarter and nine months ended December 31, 2025. The meeting was held on February 12, 2026, and concluded at 06:50 p.m. The financial results were approved as per Regulation 33 of SEBI (LODR) Regulations, 2015.

Centenial Surgical Suture Ltd has released its un-audited financial results for the quarter and nine months ended December 31, 2025. The company's total expenses for the period were Rs. 1471.89 lakhs, leading to a profit before exceptional items and tax of Rs. 19.65 lakhs. The profit for the period was Rs. 14.70 lakhs. The company operates in the Medical Devices segment and the results have been reviewed by the Audit Committee and taken on record by the Board of Directors.